Oncology · mTOR InhibitorRegulatory Approvalregulatorymid-term

FDA Grants Approval for Everolimus ANDA219464

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:31:36 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Everolimus ANDA219464 signifies a new entrant in the oncology market, which may disrupt existing competitive dynamics. Portfolio teams must evaluate the implications for market share and pricing strategies of current mTOR inhibitors. Regulatory context from FDA (FDA AP — EVEROLIMUS (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing mTOR inhibitors. The strongest clinical anchor is A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de N (ClinicalTrials.gov), moderate corpus alignment. In Oncology · mTOR Inhibitor, 7 regulatory and 4 competitive items passed relevance filtering for I3 PHARMS.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Approval for Thalidomide ANDA213267 by NATCO. This approval may increase competition in the oncology market for mTOR inhibitors, potentially impacting existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — EVEROLIMUS (ORIG) (FDA). Entity match (i3 pharms); Regulatory pathway relevance (nda). This approval indicates a successful regulatory pathway for I3 PHARMS, which may influence future submissions and compliance strategies for similar products.

Key Risks

Elevated medium regulatory exposure for I3 PHARMS could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment) could weigh on I3 PHARMS through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The introduction of I3 PHARMS' Everolimus could lead to increased competition, potentially affecting revenue and market positioning of existing mTOR inhibitors.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for I3 PHARMS may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent pricing strategies from I3 PHARMS.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — EVEROLIMUS (ORIG)
FDAhigh relevance
Entity match (i3 pharms); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — EVEROLIMUS (ORIG)
FDAhigh relevance
Entity match (everolimus); Regulatory pathway relevance (nda)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de N
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Shaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With Bruton's Tyrosine Kinase Inhibitor and B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Thalidomide ANDA213267 by NATCO
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Enzalutamide ANDA216068
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

I3 PHARMS
Everolimus

Commercial impact

medium

The introduction of I3 PHARMS' Everolimus could lead to increased competition, potentially affecting revenue and market positioning of existing mTOR inhibitors.

Regulatory impact

medium

This approval indicates a successful regulatory pathway for I3 PHARMS, which may influence future submissions and compliance strategies for similar products.

What to watch

Monitor market entry timelines and any subsequent pricing strategies from I3 PHARMS.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.